Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Cell Culture
SUBMITTER: Joe Otto
LAB HEAD: Carlos L. Arteaga
PROVIDER: PXD046996 | Pride | 2024-01-12
REPOSITORIES: Pride
Lin Chang-Ching CC Chang Tsung-Cheng TC Wang Yunguan Y Guo Lei L Gao Yunpeng Y Bikorimana Emmanuel E Lemoff Andrew A Fang Yisheng V YV Zhang He H Zhang Yanfeng Y Ye Dan D Soria-Bretones Isabel I Servetto Alberto A Lee Kyung-Min KM Luo Xuemei X Otto Joseph J JJ Akamatsu Hiroaki H Napolitano Fabiana F Mani Ram R Cescon David W DW Xu Lin L Xie Yang Y Mendell Joshua T JT Hanker Ariella B AB Arteaga Carlos L CL
Research square 20230710
CDK4/6 inhibitors (CDK4/6i) have improved survival of patients with estrogen receptor-positive (ER+) breast cancer. However, patients treated with CDK4/6i eventually develop drug resistance and progress. <i>RB1</i> loss-of-function alterations confer acquired resistance to CDK4/6i, but the optimal therapy for these patients is unclear. Using a genome-wide CRISPR screen, we identified protein arginine methyltransferase 5 (PRMT5) as a molecular vulnerability in ER+/<i>RB1</i>-knockout (RBKO) breas ...[more]